Unia Europejska - włoski - EMA (European Medicines Agency)

accord healthcare s.l.u. - plerixafor - multiple myeloma; hematopoietic stem cell transplantation - immunostimolanti, - adult patientsplerixafor accord is indicated in combination with granulocyte-colony stimulating factor (g-csf) to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in adult patients with lymphoma or multiple myeloma whose cells mobilise poorly (see section 4. paediatric patients (1 to less than 18 years)plerixafor accord is indicated in combination with g-csf to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in children with lymphoma or solid malignant tumours, either:- pre-emptively, when circulating stem cell count on the predicted day of collection after adequate mobilization with g-csf (with or without chemotherapy) is expected to be insufficient with regards to desired hematopoietic stem cells yield, or- who previously failed to collect sufficient haematopoietic stem cells (see section 4.

Włochy - włoski - AIFA (Agenzia Italiana del Farmaco)

tillomed italia srl - plerixafor - plerixafor

Włochy - włoski - AIFA (Agenzia Italiana del Farmaco)

eugia pharma (malta) limited - plerixafor - plerixafor

Włochy - włoski - AIFA (Agenzia Italiana del Farmaco)

seacross pharma (europe) ltd - plerixafor - plerixafor

Włochy - włoski - AIFA (Agenzia Italiana del Farmaco)

teva italia s.r.l. - plerixafor - plerixafor

Włochy - włoski - AIFA (Agenzia Italiana del Farmaco)

mylan s.p.a. - plerixafor - plerixafor

Unia Europejska - włoski - EMA (European Medicines Agency)

sanofi b.v. - plerixafor - multiple myeloma; hematopoietic stem cell transplantation; lymphoma - immunostimolanti, - mozobil è indicato in combinazione con il fattore distimolazione del granulocyte-per incrementare la mobilizzazione delle cellule staminali ematopoietiche al sangue periferico per la raccolta e il conseguente trapianto autologo in pazienti con linfoma e multiplo cui le cellule scarsamente mobilitare il mieloma.

Szwajcaria - włoski - Swissmedic (Swiss Agency for Therapeutic Products)

sanofi-aventis (suisse) sa - plerixaforum - soluzione iniettabile - plerixaforum 20 mg, natrii chloridum, aqua ad iniectabile q.s. ad solutionem pro 1 ml. - la mobilizzazione di cellule staminali ematopoietiche - synthetika

Unia Europejska - włoski - EMA (European Medicines Agency)

theravia - desametasone - mieloma multiplo - corticosteroidi per uso sistemico - trattamento del mieloma multiplo.

Unia Europejska - włoski - EMA (European Medicines Agency)

orchard therapeutics (netherlands) bv - atidarsagene autotemcel - leukodystrophy, metachromatic - altri farmaci sul sistema nervoso - libmeldy is indicated for the treatment of metachromatic leukodystrophy (mld) characterized by biallelic mutations in the arysulfatase a (arsa) gene leading to a reduction of the arsa enzymatic activity:in children with late infantile or early juvenile forms, without clinical manifestations of the disease,in children with the early juvenile form, with early clinical manifestations of the disease, who still  have the ability to walk independently and before the onset of cognitive decline.